Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The company is developing YB-101, a potentially first-of-its-kind antibody therapy aimed at treating Graves disease (GD) and thyroid eye disease (TED). Yarrow Bioscience was founded in October 2025 and is headquartered in New Haven, CT.
Fundamentals
Mkt Cap
$187.53M
Volume
-
52W High
$44.28
52W Low
$9.05
PE Ratio
-0.84
Avg. Volume
168,758.60
EPS (Annual)
-$30.96
P/B
0.60
Rev/Employee
$57,000.00
Earnings
-
41
Bearish Sentiment
How do you feel about VYNE?
Rulaxx1574
$VYNE an absolute dog. This is the third strike. Management show be in handcuffs. Look at the all time performance. They are taking this to zero.